GSK and XenoPort to Collaborate on Late-Stage Compound for RLS and Neuropathic Pain

doi:10.3833/pdr.v2007i81.376

Pharma Deals Review, Vol 2007, No 81 (2007)

GSK and XenoPort to Collaborate on Late-Stage Compound for RLS and Neuropathic Pain

Business Review Editor

Abstract

GlaxoSmithKline and XenoPort entered into an exclusive agreement to co-develop and commercialize XP13512 which is in Phase II trials for neuropathic pain and Phase III development for restless legs syndrome (RLS). The deal could be worth up to US$640 M.

Full Text: pdf

Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.